Alembic Pharmaceuticals Ltd (APLLTD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
41
About the Report
About the Report
Summary
Alembic Pharmaceuticals Ltd (APL) is a pharmaceutical company which manufactures and markets generic pharmaceutical products. The company's active pharmaceutical ingredients include macrolides, NSAIDs, and other drugs. It also offers branded formulations in the areas of antibiotics and antibacterial, cardiovascular, gynecological, cough and cold, gastroenterological, ophthalmological, anti-diabetic, orthopedic, urology, antihistamine, dermatological and herbal nutraceuticals. APL provides generic formulations such as anti-allergic, anthelmintic, antimicrobials, antiulcerants, nutritional and vitamin preparations, and others speciality products. The company has its research centres and manufacturing facilities in Vadodara, Gujarat and Baddi. APL is headquartered in Vadodara, Gujarat, India.
Alembic Pharmaceuticals Ltd (APLLTD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Alembic Pharmaceuticals Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Alembic Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Alembic Pharma to Form Joint Venture with Orbicular Pharma 13
TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 14
Licensing Agreements 16
Novartis Enters into Licensing Agreement with Rhizen Pharma 16
TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 17
Ranbaxy Pharma Enters Into Licensing Agreement With Alembic Pharma For Desvenlafaxine Base Extended-Release Tablets 19
Accu-Break Pharma Enters Into Licensing Agreement With Alembic Pharma To Develop Novel Pharma Products 20
Debt Offering 21
Alembic Pharma to Raise up to USD41.5 Million in Private Placement of Debentures 21
Asset Transactions 22
Alembic Pharma Sells its Formulations Manufacturing Facility to Scott-Edil Pharmacia 22
Acquisition 23
Alembic Pharma Acquires Orit Labs 23
Alembic Pharma to Acquire 49% Stake in Adwiya Mami 24
Alembic Pharmaceuticals Ltd-Key Competitors 25
Alembic Pharmaceuticals Ltd-Key Employees 26
Alembic Pharmaceuticals Ltd-Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 29
Financial Announcements 29
Jul 20, 2017: Alembic Pharmaceuticals: QI Net Revenue at Rs 648 Crores, Net Profit at Rs 65 Crores 29
May 03, 2017: Alembic Pharmaceuticals: Q4 Net Revenue grew 18% to Rs 740 Crores, Net Profit at Rs 94 cr 31
Jan 25, 2017: Alembic Pharmaceuticals: Q3 Net Profit at Rs 86 cr, Net Revenues at Rs 776 cr 32
Legal and Regulatory 33
Jun 15, 2018: Alembic Pharmaceuticals Receives Establishment Inspection Report For Its Formulation Facility At Panelav 33
May 18, 2018: Alembic Pharmaceuticals Provides Update on US FDA Inspection At its API Facility At Karkhadi 34
Apr 24, 2018: Alembic Pharmaceuticals: Update on Successful US FDA Inspection API Facility at Panelav 35
Mar 21, 2018: USFDA Inspection Formulation Facility at Panelav 36
Aug 31, 2017: Alembic Pharmaceuticals Receives EU GMP Certificate For Its Formulation Facility At Panelav 37
Mar 10, 2017: Alembic Pharmaceuticals Announces US FDA Inspection at Baroda Facility 38
Government and Public Interest 39
Apr 17, 2017: Successful US FDA Inspection at Alembic Pharmaceuticals Bioequivalence Facility at Baroda 39
Other Significant Developments 40
Aug 18, 2017: Alembic Pharmaceuticals: Disruption in plant operations at Algerian JV 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41
List of Figure
List of Figures
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Alembic Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11
List of Table
List of Tables
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alembic Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Alembic Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Alembic Pharma to Form Joint Venture with Orbicular Pharma 13
TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 14
Novartis Enters into Licensing Agreement with Rhizen Pharma 16
TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 17
Ranbaxy Pharma Enters Into Licensing Agreement With Alembic Pharma For Desvenlafaxine Base Extended-Release Tablets 19
Accu-Break Pharma Enters Into Licensing Agreement With Alembic Pharma To Develop Novel Pharma Products 20
Alembic Pharma to Raise up to USD41.5 Million in Private Placement of Debentures 21
Alembic Pharma Sells its Formulations Manufacturing Facility to Scott-Edil Pharmacia 22
Alembic Pharma Acquires Orit Labs 23
Alembic Pharma to Acquire 49% Stake in Adwiya Mami 24
Alembic Pharmaceuticals Ltd, Key Competitors 25
Alembic Pharmaceuticals Ltd, Key Employees 26
Alembic Pharmaceuticals Ltd, Other Locations 27
Alembic Pharmaceuticals Ltd, Subsidiaries 27
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.